BGNE

BeiGene, Ltd. (BGNE)

Last Price$226.70.0%
Market Cap$1,846.9M
LTM FCF to Net Income
117.3%
5Y avg
123.4%
Biotechnology industry median
84.2%
Stock quality & Intrinsic value
5/10
11.4% undervalued

BeiGene, Ltd. FCF to Net Income

Annual
Quarterly
LTM
Industry median
Company stand-alone
BGNE
Healthcare
Crunching data... Almost there!
Dec'13Dec'14Dec'15Dec'16Dec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23
FCF to Net Income
(48.3%)
50.4%
79.1%
94.8%
49.3%
102.2%
95.6%
94.5%
114.2%
98.1%
197.2%
BGNE
Key metrics and insights to make informed decisions.
View full analysis
Overvalued or undervalued?
Check the intrinsic value for BGNE and see if it's the right time to invest.
Dive in

BeiGene, Ltd. (BGNE) FCF to Net Income comparison analysis

Crunching data... Almost there!

BGNE key stats

USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
Crunching data... Almost there!

Discover more Stock Ideas

FAQ

1) What is BeiGene, Ltd.'s FCF to Net Income?

As of today, Microsoft Corp's last 12-month FCF to Net Income is 117.3%, based on the financial report for Sep 30, 2024 (Q3 2024). The average annual FCF to Net Income for BeiGene, Ltd. have been 134.1% over the past three years, and 129.5% over the past five years.

2) Is BeiGene, Ltd.'s FCF to Net Income Good?

As of today, BeiGene, Ltd.'s FCF to Net Income is 117.3%, which is higher than industry median of 84.2%. It indicates that BeiGene, Ltd.'s FCF to Net Income is Good.

3) How does BeiGene, Ltd.'s FCF to Net Income compare to its peers?

As of today, BeiGene, Ltd.'s FCF to Net Income is 117.3%, which is higher than peer median of 75.1%. The list of peers includes INCY, VRTX, ARGX, REGN, UTHR, NVO, SMMT, ALNY, BNTX, RPRX.